Using virtual reality games to improve cognitive skills in children with ADHD
Official title: Development of Virtual Reality-based Interventions to Strengthen Cognitive Skillsets Related to Attention Deficit Hyperactivity Disorder (ADHD): A Pilot Phase I and Randomized Controlled Phase II Trial
Run by National Institutes of Health Clinical Center (CC) · NCT05608434 · Data updated 2026-11-12
This study is testing if virtual reality games can help kids with ADHD improve their focus and brain skills.
Quick facts
| Phase | Phase1; Phase2 |
|---|---|
| Study type | Interventional |
| Ages | 8 Years to 16 Years |
| Sex | All |
| Enrollment | 219 (estimated) |
| Sponsor | National Institutes of Health Clinical Center (CC) NIH |
| Locations | 1 site (Bethesda, Maryland) |
| Status | Recruiting |
| Started | March 15, 2024 |
| Main results expected | September 1, 2028 |
| Study ends | November 1, 2028 |
| Registry record updated | October 8, 2026 |
| Trial ID | NCT05608434 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are children aged 8 to 16 years who have been diagnosed with ADHD.
✕Probably not a fit
Patients who do not have ADHD or those who are not willing to comply with study procedures may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial aims to evaluate the effectiveness of virtual reality-based games in enhancing cognitive skills and brain function in children aged 8 to 16 diagnosed with ADHD. Initially, a pilot study will assess the safety and feasibility of the intervention, followed by a randomized controlled trial where participants will be assigned to either a full or limited version of the VR games. The primary goal is to determine if these games can significantly reduce symptoms of inattention and improve neuropsychological performance. The study will utilize the ADHD Rating Scale-5 to measure outcomes.
Why it matters
Potential benefit: If successful, this intervention could provide a novel, engaging method for improving attention and cognitive skills in children with ADHD.
How similar studies have gone: While the use of virtual reality for cognitive training is an emerging field, this specific approach targeting ADHD is relatively novel and has not been extensively tested in prior studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
* INCLUSION CRITERIA: In order to be eligible to participate, an individual must meet all of the following criteria: 1. Children must provide informed assent and parents must provide informed consent to participate in the study. 2. Any sex assigned at birth, or race/ethnicity. 3. Aged between 8 and 16 years of age, including all months leading up to age 17. For the pilot only, the minimum age was 10 years (i.e., pilot participants were aged 10 to 16 years, including all months leading up to age 17). 4. Meets diagnosis for ADHD, predominately inattentive or combined presentations, or a specified presentation of having prominent symptoms of inattention that are impairing in two or more settings (but not numerous enough to meet a diagnosis of inattentive or combined presentation). 5. A score of \>12 on the ADHD-RS-5 inattention subscale at the screening/baseline assessment. For participants receiving ADHD medication at the time of assessment, the rating will reflect current (i.e., on-medication) symptom levels. 6. Stated willingness to comply with all study procedures and lifestyle considerations, availability for the duration of the study, and ability to travel to the NIH Clinical Center for the scheduled in-person study visits. 7. For the Pilot only: If treated for ADHD with psychostimulants, willing to withdraw medication three days prior to baseline assessments and to stay off medication until completion of the post-intervention assessment. Not receiving any other psychotropic medication for at least 30 days prior to baseline assessment. EXCLUSION CRITERIA: An individual who meets any of the following criteria will be excluded from participation in this study: 1. Cognitively not capable of performing study procedures. Indications of a lack of cognitive capacity could include a known IQ under 70, or a history from the screening interview that implies global intellectual disabilities (e.g., placement in a school for children with intellectual disability etc.) 2. History of severe migraines, vertigo, epilepsy (with the exception of febrile seizures), or serious balance disorders. 3. Impairments in uncorrected visual acuity that would interfere with engagement with the VR training. 4. Known to be pregnant. 5. Psychotic disorders (including schizophrenia, psychosis not otherwise specified), current substance dependence. Other psychiatric disorders elicited on the interview are not considered exclusionary provided that ADHD is considered to be one of the dominant sources of impairment for the child. 6. Considered a suicide risk as determined during the clinical interview at baseline. 7. Any other medical or psychiatric condition that in the opinion of the PI may confound study data/assessments (e.g., limitations in mobility that would render the VR headset unusable). 8. Recent (within three months) treatment with other cognitive training interventions (e.g., Cogmed) for ADHD. 9. The VR equipment produces excessive discomfort to the child in the opinion of the PI (e.g., including participants with small interpupillary distances (IPD) that are only able to see blurry images on the VR headset, or children showing signs of undue neck and upper body strain or fatigue while trying the headset). 10. For the main trial only: Certain psychotropic medications classes that are likely to interfere with the completion of the intervention are exclusionary: antipsychotics, mood stabilizers (lithium, valproate, lamotrigine, gabapentin). In addition, regular use of any other psychoactive (non-stimulant) medication that, in the opinion of the Investigator, may confound study data or interfere with completion of the intervention is exclusionary. Medications for ADHD will not be considered as exclusionary. This includes psychostimulants, atomoxetine, alpha 2 adrenergic agonists. Antidepressant and anxiolytic medication will also not be exclusionary if they are deemed not to interfere with study procedures 11. For the main trial only: Prior use of Floreo's products including but not limited to their ADHD cognitive training application.
Where it's running
-
National Institutes of Health Clinical Center
Bethesda, Maryland, United States Recruiting
Study contacts
- Principal investigator: Daniel S Pine, M.D. — National Institute of Mental Health (NIMH)
- Study coordinator: Saadia A Choudhury
- Email: saadia.choudhury@nih.gov
- Phone: (301) 437-0489
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Foquest in older adults with ADHD: daily methylphenidate for 65+
This study tests whether once-daily Foquest helps symptoms in adults 65 and older with ADHD.
-
Neuroplasticity-targeted supplements for ADHD in children
A 12-week randomized trial tests whether gut- and brain-targeted supplements can help reduce ADHD symptoms in children aged 6–12.
-
Therapy approaches for irritability in youths: active treatments vs nonactive psychoeducation
This study tests whether active psychotherapies for irritability in kids aged 8–16.5 years work better than nonactive, time-matched psychoeducation for children and their parents.
-
Playful physiotherapy to support children with ADHD or autism
This program will try a play-based physiotherapy approach to see if it improves emotional, behavioral, and social functioning in Estonian-speaking children aged 5–12 with ADHD or autism.
-
Social cognition testing for 8–16-year-olds with autism, ADHD, or atypical development
This project will test a multidimensional social-cognition battery in French-speaking 8–16-year-olds with autism, ADHD, or atypical neurodevelopment to see if it better identifies social processing differences.
-
Transcranial infrared light to the prefrontal cortex for adults with ADHD
This trial will try using transcranial infrared light on the prefrontal cortex to see if it improves attention, impulse control, and working memory in adults with ADHD.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.